LQDA earnings analysis
What we found in LQDA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing indicates that Liquidia maintained profitability and positive operating cash flow through the first two quarters of 2026, although the provided excerpt does not contain the current quarter’s revenue, EPS, margins, segment results, balance-sheet balances or cash-flow amounts. The investment case remains concentrated in YUTREPIA, with an accumulated deficit of $498.7 million and a $15.0 million minimum cash covenant under the HCR facility. Ongoing United Therapeutics litigation, the CADD-MS-3 pump replacement issue, and newly emphasized tariff and geopolitical risks offset the improving operating trajectory.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Profitability Continued Through Q2
- Management states that the company achieved profitability and positive cash flows in both the first and second quarters of 2026, extending the improvement reflected in the supplied history from a $0.52 diluted EPS profit and $50 million of FCF in Q1 2026.
- Losses Narrowed Historically
- The company had an accumulated deficit of $498.7 million as of June 30, 2026, but reported historical annual net losses of $68.9 million in 2025 versus $128.3 million in 2024.
- Controls Remained Effective
- Disclosure controls and procedures were concluded effective at the reasonable assurance level as of June 30, 2026, and management reported no changes in internal control that materially affected, or were reasonably likely to materially affect, financial reporting.
- Broad Public Share Availability
- As of July 29, 2026, 83,139,121 shares, or 92.9% of outstanding shares, were freely tradable without restriction or further registration under the Securities Act.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- YUTREPIA Litigation Remains Critical
- United Therapeutics has multiple pending patent and trade-secret proceedings, including the ‘327 Patent Litigation and the ‘782 Patent Litigation. The company states that an adverse outcome could require YUTREPIA to be withdrawn or could stop commercialization for one or both indications; the ‘327 trial was held in June 2025 and the ‘782 complaint was filed in May 2025.
- Treprostinil Pump Constraint
- The company states that ICU Medical no longer manufactures or supports the CADD-MS-3 infusion pump used for subcutaneous Treprostinil Injection. Available pumps are expected to be sufficient only through at least the end of 2026, and neither Liquidia nor Sandoz had submitted a 510(k) application for a replacement pump as of the filing.
- Tariff and Supply-Chain Exposure
- The filing newly emphasizes tariff and geopolitical exposure across the supply chain: APIs, devices and raw materials are sourced from South Korea, Taiwan, China, Italy and elsewhere, while Sandoz sources treprostinil from Canada. It also cites an April 2026 executive order seeking a 100% tariff on certain imported branded or patented pharmaceuticals.
- HCR Covenant and Liquidity Risk
- The company must maintain a minimum cash balance of $15.0 million under its HCR financing agreement. A covenant breach or material adverse event could permit acceleration and foreclosure on collateral, including intellectual property.
- Concentration in YUTREPIA
- The company remains primarily dependent on YUTREPIA and L606 while having only one approved product; YUTREPIA received FDA approval in May 2025 and began commercialization in June 2025. The filing states that sustained revenue, profitability and positive cash flow from YUTREPIA remain uncertain.
What they said about what is next.
The provided 10-Q excerpt does not include quantitative Q2 2026 revenue, EPS, margin, segment, or cash-flow guidance. Management states that profitability and positive cash flow were achieved in the first two quarters of 2026, but no forward numerical outlook is provided.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- Liquidia Corporation reported exceptionally strong Q1 2026 results, with total revenues hitting $132.9 million, representing a significant increase compared to prior periods. The financial highlights include net income…
- 10-K · March 5, 2026
- Liquidia’s 10-K documents a clear commercial inflection following FDA approval of YUTREPIA in May 2025 and launch in June 2025, with revenue ramping to $92,021,000 in Q4 2025 and margins and cash flow turning positive.…
- 10-Q · May 8, 2025
- Liquidia reported Q1 revenue of $3,120,000 (up from $2,972,000 year-over-year) and a GAAP net loss per share of $(0.45) (vs. $(0.40) year‑ago). Gross margin held at ~51.4% while operating loss widened to $35,425,000,…
- 10-Q · August 7, 2024
- Liquidia reported Q2 revenue of $3.659M (down $1.127M or -23.6% YoY from $4.786M; up $0.687M or +23.1% QoQ from $2.972M). Gross margin improved sequentially to 59.2% but collapsed YoY from ~86.0%; operating loss…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LQDA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever